News

FDA proposes higher fees for drug approvals to cover postmarketing surveillance

BMJ 2007; 334 doi: 10.1136/bmj.39104.352616.DB (Published 25 January 2007)
Cite this as: BMJ 2007;334:177.3

Access to the full text of this article requires a subscription or payment. Please log in or subscribe below.

  1. Janice Hopkins Tanne
  1. 1New York

    The US Food and Drug Administration has agreed with pharmaceutical manufacturers on an almost 30% increase in the “user fees” that drug makers pay to the FDA to expedite approval of new drugs. The FDA has also consulted patient advocates, consumer groups, health professionals, and academic researchers about the new rules.

    User fees are annual fees paid by pharmaceutical manufacturers. The FDA wants them to increase by $87.4m to $392.8m (£199.0m; €303.7m). The FDA now gets more than half of its funding from user fees.

    The agency will hold a public meeting in Washington, DC, on 16 February to hear comments and will then ask Congress to approve the new rules.

    The FDA says the largest portion of the new fees—$29.3m—will …

    Access to the full text of this article requires a subscription or payment

    Subscribe

    Article access

    Article access for 1 day

    Purchase this article for £20 $30 €32*

    The PDF version can be downloaded as your personal record

    * Prices do not include VAT

    Rapid responses

    THIS WEEK'S POLL

    BMJ most popular